Literature DB >> 9157962

Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism.

J Frostegård1, Y H Huang, J Rönnelid, L Schäfer-Elinder.   

Abstract

Platelet activating factor (PAF) is a phospholipid with proinflammatory and thrombogenic properties, which has been implicated in inflammatory disorders including vasculitis and asthma. PAF-like compounds are present in oxidized LDL (oxLDL), which has been detected in the atherosclerotic lesion, where it may activate monocytes, macrophages, and T cells. OxLDL may therefore both initiate and perpetuate inflammatory reactions in the artery wall. Herein we demonstrate that PAF has the capacity to induce enhanced interferon gamma (IFN-gamma) secretion in peripheral blood mononuclear leukocytes (PBMCs), as does oxLDL. Both oxLDL- and PAF-induced IFN-gamma secretions were inhibited by a specific PAF-receptor antagonist, WEB 2170. PAF-like lipids in oxLDL could thus be responsible for oxLDL-induced activation of immune-competent cells. The effects of PAF and oxLDL were inhibited by antibodies to major histocompatibility complex class II and thus depend on accessory cells like monocytes. Both PAF and oxLDL induced tumor necrosis factor-alpha (TNF-alpha) synthesis in peripheral blood. PAF-mediated TNF-alpha production was inhibited by WEB 2170, whereas oxLDL-induced TNF-alpha was only partially inhibited. These findings indicate that both PAF and oxLDL have the capacity to induce TNF-alpha, which may increase atherogenesis due to its pleiotropic proinflammatory effects. Our findings suggest that the PAF receptor plays an important role in the inflammatory component of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9157962     DOI: 10.1161/01.atv.17.5.963

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis.

Authors:  H Bruunsgaard; P Skinhøj; A N Pedersen; M Schroll; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Interleukin-8 and its receptor CXCR2 in atherosclerosis.

Authors:  W A Boisvert; L K Curtiss; R A Terkeltaub
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism.

Authors:  Y H Huang; L Schäfer-Elinder; R Wu; H E Claesson; J Frostegård
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus.

Authors:  R Wu; E Svenungsson; I Gunnarsson; C Haegerstrand-Gillis; B Andersson; I Lundberg; L S Elinder; J Frostegård
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

5.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.

Authors:  W A Boisvert; R Santiago; L K Curtiss; R A Terkeltaub
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

6.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

Review 7.  The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.

Authors:  Theodoros Kelesidis; Vasiliki Papakonstantinou; Paraskevi Detopoulou; Elizabeth Fragopoulou; Maria Chini; Marios C Lazanas; Smaragdi Antonopoulou
Journal:  AIDS Rev       Date:  2015 Oct-Dec       Impact factor: 2.500

8.  Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality.

Authors:  A G Frostegård; X Hua; J Su; J J Carrero; O Heimbürger; P Bárány; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

9.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.